Recombinant Lactic Acid Bacteria As Promising Vectors for Mucosal Vaccination

Overview

Journal Exploration (Beijing)

Specialty Biomedical Engineering

Date 2023 Jun 16

PMID 37323212

Authors

Nan Qiao

Guangsheng Du

Xiaofang Zhong

Xun Sun

Affiliations

Soon will be listed here.

Abstract

Lactic acid bacteria (LAB), a diverse family of gram-positive bacteria, has been proven effective in delivering varieties of therapeutic and prophylactic molecules such as antigens and cytokines. Featuring the properties of acid-resistant, high uptake into Peyer's patches, and superior capacity for inducing secretory IgA antibodies, LAB have good potential to be used as vaccine vectors for mucosal vaccination. Mucosal immunization enables both mucosal and systemic immune responses, which are critical for resisting pathogens that invade the host through the mucosal surfaces. With the development of genetic engineering, LAB strains, primarily and have been exploited to express a range of heterologous antigens. Numerous studies have demonstrated that LAB mucosal vaccines can stimulate all arms of the immune system to provide adequate protection against pathogen infections. Additionally, several LAB-based human vaccines have entered the clinical trial studies, which suggest the great promise of LAB vaccines for new interventions in mucosal transport diseases. Herein, we will discuss the factors that influence the immunogenicity of LAB vaccines, including LAB strains, the location of antigens, and administration routes, and focus on the current strategies that have been reported for optimizing LAB vaccines.

Citing Articles

Maternal Milk Orchestrates the Development of Infant Gut Microbiota: Implications for Health and Future Research Directions.

Wang R, Sun S, Zhang Q, Wu G, Ren F, Chen J Research (Wash D C). 2025; 8:0558.

PMID: 39975576 PMC: 11836195. DOI: 10.34133/research.0558.

Effect of synbiotic supplementation on obesity and gut microbiota in obese adults: a double-blind randomized controlled trial.

Niu X, Zhang Q, Liu J, Zhao Y, Shang N, Li S Front Nutr. 2024; 11:1510318.

PMID: 39664910 PMC: 11633458. DOI: 10.3389/fnut.2024.1510318.

Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.

Lu J, Shen X, Li H, Du J Exploration (Beijing). 2024; 4(5):20230142.

PMID: 39439496 PMC: 11491310. DOI: 10.1002/EXP.20230142.

Physiochemically and Genetically Engineered Bacteria: Instructive Design Principles and Diverse Applications.

Lin X, Jiao R, Cui H, Yan X, Zhang K Adv Sci (Weinh). 2024; 11(30):e2403156.

PMID: 38864372 PMC: 11321697. DOI: 10.1002/advs.202403156.

Production of Promising Heat-Labile Enterotoxin (LT) B Subunit-Based Self-Assembled Bioconjugate Nanovaccines against Infectious Diseases.

Li C, Li J, Sun P, Li T, Yan X, Ye J Vaccines (Basel). 2024; 12(4).

PMID: 38675730 PMC: 11054625. DOI: 10.3390/vaccines12040347.

References

Mielcarek N, Alonso S, Locht C . Nasal vaccination using live bacterial vectors. Adv Drug Deliv Rev. 2001; 51(1-3):55-69. DOI: 10.1016/s0169-409x(01)00168-5. View

Li H, Piao D, Jiang T, Bok J, Cho C, Lee Y . Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization. Vaccine. 2015; 33(16):1959-67. DOI: 10.1016/j.vaccine.2015.02.061. View

Kim S, Jung D, Yang I, Kim J, Lee K, Nochi T . M cells expressing the complement C5a receptor are efficient targets for mucosal vaccine delivery. Eur J Immunol. 2011; 41(11):3219-29. DOI: 10.1002/eji.201141592. View

Allaire J, Crowley S, Law H, Chang S, Ko H, Vallance B . The Intestinal Epithelium: Central Coordinator of Mucosal Immunity: (Trends in Immunology 39, 677-696, 2018). Trends Immunol. 2019; 40(2):174. DOI: 10.1016/j.it.2018.12.008. View

Yu M, Qi R, Chen C, Yin J, Ma S, Shi W . Immunogenicity of recombinant Lactobacillus casei-expressing F4 (K88) fimbrial adhesin FaeG in conjunction with a heat-labile enterotoxin A (LTAK63) and heat-labile enterotoxin B (LTB) of enterotoxigenic Escherichia coli as an oral adjuvant in mice. J Appl Microbiol. 2016; 122(2):506-515. DOI: 10.1111/jam.13352. View

Peng X, Zhang R, Wang C, Yu F, Yu M, Chen S . Enterotoxin LtB Enhances Vaccine-Induced Anti- Protection by Promoting Leukocyte Migration into Gastric Mucus via Inflammatory Lesions. Cells. 2019; 8(9). PMC: 6770474. DOI: 10.3390/cells8090982. View

Cronin M, Sleator R, Hill C, Fitzgerald G, Van Sinderen D . Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice. BMC Microbiol. 2008; 8:161. PMC: 2564955. DOI: 10.1186/1471-2180-8-161. View

Pickard J, Chervonsky A . Sampling of the intestinal microbiota by epithelial M cells. Curr Gastroenterol Rep. 2010; 12(5):331-9. DOI: 10.1007/s11894-010-0128-x. View

Peng X, Zhang R, Duan G, Wang C, Sun N, Zhang L . Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity. Sci Rep. 2018; 8(1):6435. PMC: 5915382. DOI: 10.1038/s41598-018-24879-x. View

10.

Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A . Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine. 2014; 32(47):6233-9. DOI: 10.1016/j.vaccine.2014.09.020. View

11.

Marelli B, Perez A, Banchio C, de Mendoza D, Magni C . Oral immunization with live Lactococcus lactis expressing rotavirus VP8 subunit induces specific immune response in mice. J Virol Methods. 2011; 175(1):28-37. DOI: 10.1016/j.jviromet.2011.04.011. View

12.

Cesta M . Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006; 34(5):599-608. DOI: 10.1080/01926230600865531. View

13.

Li R, Chowdhury M, Kim J, Kim T, Pathinayake P, Koo W . Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes. Vet Microbiol. 2015; 179(3-4):250-63. DOI: 10.1016/j.vetmic.2015.07.020. View

14.

Pizza M, Giuliani M, Fontana M, Monaci E, Douce G, Dougan G . Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 2001; 19(17-19):2534-41. DOI: 10.1016/s0264-410x(00)00553-3. View

15.

Bermudez-Humaran L . Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin. 2009; 5(4):264-7. DOI: 10.4161/hv.5.4.7553. View

16.

Kajikawa A, Zhang L, Long J, Nordone S, Stoeker L, LaVoy A . Construction and immunological evaluation of dual cell surface display of HIV-1 gag and Salmonella enterica serovar Typhimurium FliC in Lactobacillus acidophilus for vaccine delivery. Clin Vaccine Immunol. 2012; 19(9):1374-81. PMC: 3428403. DOI: 10.1128/CVI.00049-12. View

17.

Wallace T, Guarner F, Madsen K, Cabana M, Gibson G, Hentges E . Human gut microbiota and its relationship to health and disease. Nutr Rev. 2011; 69(7):392-403. DOI: 10.1111/j.1753-4887.2011.00402.x. View

18.

Bermudez-Humaran L, Kharrat P, Chatel J, Langella P . Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact. 2011; 10 Suppl 1:S4. PMC: 3231930. DOI: 10.1186/1475-2859-10-S1-S4. View

19.

Ikeda Y, Uemura Y, Asai-Sato M, Nakao T, Nakajima T, Iwata T . Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized.... Jpn J Clin Oncol. 2019; 49(9):877-880. DOI: 10.1093/jjco/hyz095. View

20.

Park Y, Ouh Y, Sung M, Park H, Kim T, Cho C . A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3. J Gynecol Oncol. 2019; 30(6):e88. PMC: 6779607. DOI: 10.3802/jgo.2019.30.e88. View